Business
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagementVMT-α-NET continues to be well-tolerated and shows durable disease control and deepening of tumor response with longer follow-up as reported at ASCO-GI 2026 Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP acros
About this update from Perspective Therapeutics, Inc.
[{"type":"image","alt":"Perspective Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Perspective Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QSFbVndZiJCez3FgWA5yTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9","width":300,"height":63}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p","attribs":{}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagement","length":238,"tagName":"p"}]},{"val":[{"type":"text","content":"VMT-α-NET continues to be well-tolerated and shows durable disease control and deepening of tumor response with longer follow-up as reported at ASCO-GI 2026 ","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP across multiple solid tumors, as well as potential additions to the clinical pipeline to be guided by first-in-human images","length":223,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to present updates at 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 2:15 p.m. PT","length":123,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":740,"olType":false},{"type":"text","content":"SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, today announced certain business updates and strategic priorities for the next 12-18 months.","length":357,"tagName":"p"},{"type":"text","content":"“In 2026, I look forward to building on the immense progress made by everyone at Perspective during 2025 in applying our proprietary next generation targeted radiopharmaceutical technology to ...